Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …
Lipoprotein (a) and its significance in cardiovascular disease: a review
FD Lau, RP Giugliano - JAMA cardiology, 2022 - jamanetwork.com
Importance Lipoprotein (a)(Lp [a]) is a low-density lipoprotein (LDL) cholesterol–like particle
bound to apolipoprotein (a). This novel marker of cardiovascular disease acts through …
bound to apolipoprotein (a). This novel marker of cardiovascular disease acts through …
[HTML][HTML] Small interfering RNA to reduce lipoprotein (a) in cardiovascular disease
ML O'Donoghue, RS Rosenson… - … England Journal of …, 2022 - Mass Medical Soc
Background Lipoprotein (a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label …
KK Ray, RPT Troquay, FLJ Visseren… - The Lancet Diabetes & …, 2023 - thelancet.com
Introduction Whether long-term treatment with the twice-yearly, siRNA therapeutic inclisiran,
which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9) …
which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9) …
Muvalaplin, an oral small molecule inhibitor of lipoprotein (a) formation: a randomized clinical trial
Importance Lipoprotein (a)(Lp [a]) is associated with atherosclerotic disease and aortic
stenosis. Lp (a) forms by bonding between apolipoprotein (a)(apo [a]) and apo B 100 …
stenosis. Lp (a) forms by bonding between apolipoprotein (a)(apo [a]) and apo B 100 …
Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein (a): a randomized dose-ascending clinical trial
Importance Epidemiological and genetic data have implicated lipoprotein (a) as a potentially
modifiable risk factor for atherosclerotic disease and aortic stenosis, but there are no …
modifiable risk factor for atherosclerotic disease and aortic stenosis, but there are no …
A focused update to the 2019 NLA scientific statement on use of lipoprotein (a) in clinical practice
Since the 2019 National Lipid Association (NLA) Scientific Statement on Use of Lipoprotein
(a) in Clinical Practice was issued, accumulating epidemiological data have clarified the …
(a) in Clinical Practice was issued, accumulating epidemiological data have clarified the …
[HTML][HTML] Inflammation, Cholesterol, Lipoprotein (a) and 30-Year Cardiovascular Outcomes in Women
Background High-sensitivity C-reactive protein (hsCRP), low-density lipoprotein cholesterol
(LDL-C), and lipoprotein (a)[Lp (a)] contribute to 5-year and 10-year predictions of …
(LDL-C), and lipoprotein (a)[Lp (a)] contribute to 5-year and 10-year predictions of …
[HTML][HTML] Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a)-DOSE)
ML O'Donoghue, JAG López, B Knusel, B Gencer… - American Heart …, 2022 - Elsevier
Background Data support lipoprotein (a)(Lp [Lp (a)]) being a risk factor for atherosclerotic
cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that …
cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that …
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
J Brandts, KK Ray - Nature Reviews Cardiology, 2023 - nature.com
Lowering the levels of LDL cholesterol in the plasma has been shown to reduce the risk of
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …